<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880239</url>
  </required_header>
  <id_info>
    <org_study_id>STU00214588</org_study_id>
    <nct_id>NCT04880239</nct_id>
  </id_info>
  <brief_title>REDUCE Trial- Reducing Prolapse Recurrence</brief_title>
  <official_title>REDUCE Trial - Reducing Prolapse Recurrence by Reducing the Genital Hiatus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Institute of Pelvic Medicine &amp; Reconstructive Surgery, Allentown, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether surgeons should add a prophylactic posterior&#xD;
      colpoperineorrhaphy to a mesh-augmented apical prolapse repair.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The decision to perform a posterior colpoperineorrhaphy at the time of sacrocolpopexy is&#xD;
      controversial. Based on cohort data, some surgeons advocate that sacrocolpopexy alone is&#xD;
      effective at treating posterior vaginal wall prolapse and the addition of posterior&#xD;
      colpoperineorrhaphy only increases the likelihood of pain with defecation and dyspareunia.&#xD;
      Experts theorize that placement of posterior vaginal mesh down to the perineal body provides&#xD;
      adequate posterior support and reduces genital hiatus size. Others argue that placement of&#xD;
      mesh too low on the posterior vagina may be associated with increased mesh exposure and pain&#xD;
      secondary to mesh stiffness. No randomized trials exist comparing prolapse outcomes using&#xD;
      new, ultra-light polypropylene mesh with and without posterior colpoperineorrhaphy. The&#xD;
      investigators hypothesize that there will be no difference in prolapse outcomes after&#xD;
      sacrocolpopexy using Restorelle mesh with and without posterior colpoperineorrhaphy. However,&#xD;
      patients with a posterior colpoperineorrhaphy will be more likely to report pain with&#xD;
      defecation and dyspareunia. This will be the first multicenter randomized trial comparing&#xD;
      outcomes of sacrocolpopexy with and without posterior colpoperineorrhaphy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Organ Prolapse Quantification (POP-Q) System</measure>
    <time_frame>1 Year</time_frame>
    <description>The POP-Q System will be used to compare the rate of prolapse recurrence at 1 year between women undergoing a sacrocolpopexy with Restorelle mesh with and without a concomitant posterior colpoperineorrhaphy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Defecatory Dysfunction</measure>
    <time_frame>1 Year</time_frame>
    <description>To compare the rates of defecatory dysfunction using the Bristol Stool Scale (stool types measured from type 1-type 7) and the Colorectal-Anal Distress Inventory 8 (measured from 0-100 points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia</measure>
    <time_frame>1 Year</time_frame>
    <description>To compare the rates of dyspareunia between groups using the Female Sexual Function Index (measured from 2-36 points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical and Perioperative Events: Blood Loss</measure>
    <time_frame>2 Weeks</time_frame>
    <description>To compare the estimated blood loss (in milliliters) between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical and Perioperative Events: Operative Time</measure>
    <time_frame>Day of surgery</time_frame>
    <description>To compare the operative time (in minutes as listed on the surgical case tracking) between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical and Perioperative Events: Postoperative Pain</measure>
    <time_frame>2 Weeks</time_frame>
    <description>To compare postoperative pain scores using a visual analog scale (0-100 points) between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical and Perioperative Events: Pain Medication Use</measure>
    <time_frame>2 Weeks</time_frame>
    <description>To compare narcotic pain medication use (in morphine equivalents consumed and reported by patients) between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prolapse; Female</condition>
  <arm_group>
    <arm_group_label>Sacralcolpopexy with posterior colpoperineorrhaphy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sacralcolpopexy without posterior colpoperineorrhaphy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterior colpoperineorrhaphy</intervention_name>
    <description>Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy</description>
    <arm_group_label>Sacralcolpopexy with posterior colpoperineorrhaphy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over the age of 18&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Symptomatic prolapse (stage II or greater) undergoing minimally-invasive&#xD;
             sacrocolpopexy with Restorelle ultra lightweight mesh&#xD;
&#xD;
          -  Preoperative genital hiatus with valsalva/strain greater than or equal to 4cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has had prior prolapse surgery&#xD;
&#xD;
          -  Patient has inflammatory bowel disease (Crohn's, Ulcerative Colitis)&#xD;
&#xD;
          -  Baseline dyspareunia (patient reports that they have pain with vaginal intercourse&#xD;
             when asked as a yes/no)&#xD;
&#xD;
          -  Patients with a score of 7 or greater in any one muscle on the Meister Pelvic Floor&#xD;
             Exam&#xD;
&#xD;
          -  Patient planning a concomitant Burch procedure&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Geynisman-Tan, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pooja Sharma, BS, BA, BMS</last_name>
    <phone>312-926-7846</phone>
    <email>pooja.sharma@nm.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylwia Clarke, BA</last_name>
    <phone>312-695-7748</phone>
    <email>sylwia.clarke@nm.org</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Julia Geynisman-Tan</investigator_full_name>
    <investigator_title>Director of Research; Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

